|
A novel pancreatic cancer vaccine shows promise in improving survival when added to standardtreatment, according to new research out of University HospitalsCase Medical Center's Seidman Cancer Center and Case WesternReserve University School of Medicine. The Phase 2 data waspresented at the Annual Meeting of the Society for Surgery of theAlimentary Tract, part of Digestive Disease Week in San Diego. In the plenary session titled "Addition of Algenpantucel-LImmunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: aPhase 2 Study" (PT Abstract # 028), Jeffrey Hardacre, MD, leadinvestigator, presented the updated data. The multi-site,nationwide study involved 70 patients with resected pancreaticcancer and suggests improvement in 12-month disease-free andoverall survival. "Pancreatic cancer is a deadly disease with long-term survival lessthan 5%," says Dr. Hardacre, surgical oncologist with UH CaseMedical Center and Associate Professor at Case Western ReserveUniversity School of Medicine. "Better treatments are needed toimprove survival and we are encouraged by the promising results ofthis vaccine therapy." The vaccine, known as Algenpantucel-L, is unique from otherapproaches in that it is designed to trigger the patient's ownimmune system to destroy cancer cells. Algenpantucel-L, developed by NewLink Genetics Corporation,was added to standard adjuvant therapy for patients who havesuccessfully undergone pancreatic surgical resection. A pivotal, nationwide Phase 3 study of the vaccine, also led inpart by Dr. Hardacre, has begun and will involve up to 722patients. Cancer of the pancreas is the fourth leading cause of cancer deathin the United States, killing more than 35,000 Americans each year.Pancreatic cancer is characteristically aggressive withnon-specific initial symptoms, making it difficult to diagnoseearly. Conventional therapies have little impact on prognosis anddisease outcome. Surgical resection of the tumor is currently theonly chance for a cure. Without resection, overall median survivalis four to six months with an estimated five-year survival rate of0.4 percent to 5 percent. "Patients with pancreatic cancer have limited options and therehave been few advances for this lethal disease in recent years,"says Stan Gerson, MD, Director of the UH Seidman Cancer Center andthe Case Comprehensive Cancer Center at Case Western ReserveUniversity. "We are proud that Jeff and our cancer center haveplayed such a significant role in investigating this promising newtreatment option." Additional References Citations. I am an expert from chinamachinemanufacturer.com, while we provides the quality product, such as China 4G Wireless Technology , Copper Annealing Furnace, Notching Machines,and more.
Related Articles -
China 4G Wireless Technology, Copper Annealing Furnace,
|
